Arrowhead Research | ARWR - Des Atouts





Des Atouts Changement Date
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Novartis USD 118.53B 7.58B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
TG Therapeutics USD 1.53B 465.58M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xencor USD 736.85M 138.65M 2026-03